Two pathways, one weekly injection.
Weekly subcutaneous injection
Tirzepatide acts on both GIP and GLP-1 receptors — two gut-hormone pathways involved in appetite and blood-sugar regulation. An independent licensed provider considers it case by case, and only where treatment is appropriate.
Prescription required. Compounded medications are not approved or evaluated by the FDA for safety, effectiveness, or quality. A licensed provider will determine whether treatment is appropriate for you.
What is compounded tirzepatide?
Tirzepatide is a dual-agonist medication: it activates both GLP-1 and GIP receptors, two gut-hormone pathways involved in appetite, glucose response, and how the body stores energy. Like semaglutide, it is taken as a weekly subcutaneous injection and has been clinically studied for weight management.
A second pathway does not automatically make it the right choice. Which mechanism suits you — and whether medication is appropriate at all — depends on your health history, your goals, and how any earlier treatment has gone. That judgment belongs to the independent licensed provider who reviews your case. Individual results vary, and no outcome is guaranteed.
Compounded tirzepatide is prepared by a state-licensed compounding pharmacy for an individual patient, pursuant to a licensed provider's prescription. It is not FDA-approved, and it is not the same as any branded tirzepatide product.
How treatment works
Activates GLP-1 receptors
Like semaglutide, tirzepatide acts on GLP-1 receptor pathways — supporting appetite regulation, slowing gastric emptying, and steadying the body's insulin response.
Also activates GIP receptors
GIP — glucose-dependent insulinotropic polypeptide — is a second gut hormone involved in glucose handling and energy storage. Tirzepatide engages both pathways at once, which is what distinguishes its mechanism.
Titrated with extra care
If prescribed, treatment begins at a low dose that the reviewing provider increases gradually, with room to slow down or pause along the way. Careful titration is how providers work to keep side effects manageable.
Tirzepatide and semaglutide, compared
Tirzepatide
- Acts on both GIP and GLP-1 receptor pathways
- Weekly subcutaneous injection
- Considered case by case by the reviewing provider
- Titrated gradually, with particular care
Semaglutide
- Acts on the GLP-1 receptor pathway alone
- Weekly subcutaneous injection
- The more widely studied of the two
- Often the first option a provider considers
Important safety information
Compounded medications are prepared by a state-licensed compounding pharmacy for an individual patient pursuant to a licensed provider's prescription. They are not FDA-approved, and the FDA does not review compounded medications for safety, effectiveness, or quality before they are dispensed. Compounded medications are not the same as, and are not generic versions of, any FDA-approved medication.
Who should not use tirzepatide
The contraindications mirror other GLP-1 medications: a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), pregnancy or breastfeeding, or a history of pancreatitis, severe gastrointestinal disease, or significant kidney disease. This list is not exhaustive — the reviewing provider makes the final decision.
Common side effects
Nausea, constipation, heartburn, fatigue, and injection-site reactions are the most common, especially during dose increases. The profile is broadly similar to semaglutide's. A slower titration schedule, smaller meals, and steady hydration help, and the prescribing provider can adjust the plan if an effect persists.
Serious but rare risks
Pancreatitis, gallbladder problems, allergic reactions, and changes in vision for people with diabetic retinopathy are rare but serious. Severe or persistent abdominal pain, pain radiating to the back, vomiting that will not stop, or a sudden change in vision are reasons to seek care promptly.
Drug interactions
Share every medication and supplement you take during your consultation — prescription, over-the-counter, and herbal. Medications that lower blood sugar deserve particular attention, since combining them with GLP-1 treatment can require closer monitoring. The reviewing provider evaluates your full profile before any prescription is written.
Pregnancy and breastfeeding
Tirzepatide is not recommended during pregnancy, while breastfeeding, or while actively trying to conceive. If your circumstances change during treatment, tell the prescribing provider promptly.
If a side effect appears
Contact the prescribing provider first — dose pauses and slower schedules resolve many early effects. For a severe allergic reaction, difficulty breathing, severe abdominal pain, or anything that feels like an emergency, call 911 or go to the nearest emergency room first.
Questions, answered.
Semaglutide acts on GLP-1 receptors alone; tirzepatide acts on both GIP and GLP-1 receptor pathways. Neither is automatically better. Which mechanism — if either — is appropriate for you is the reviewing provider's decision, based on your health history, your goals, and how any earlier treatment has gone.
No. Compounded tirzepatide is not the same as, and is not a generic version of, Mounjaro®, Zepbound®, or any other FDA-approved medication.
It is prepared by a state-licensed compounding pharmacy for an individual patient pursuant to a provider's prescription, and it is not FDA-approved — the FDA does not review compounded medications for safety, effectiveness, or quality.
No one can promise you that, and we never will. No specific amount of weight loss can be guaranteed with any medication, and individual results vary widely. What can be said is mechanistic: the two medications work through different receptor pathways, and the reviewing provider weighs which — if either — fits your situation.
Yes. Compounded tirzepatide is a prescription medication, available only if an independent licensed provider determines that a prescription is appropriate after a required medical consultation. It is never dispensed without one.
Eligibility is a medical decision made by an independent licensed provider — completing the assessment does not guarantee a prescription, and sometimes the honest answer is no. Services are not available in all states; see our States Served page for details.
A short set of questions about your goals, health background, and lifestyle, reviewed by an independent licensed provider who determines whether prescription treatment is appropriate — and if so, which medication. Our How It Works page walks through the full process.
Start with the prescribing provider — many early side effects settle with a dose pause or a slower schedule. Our Safety page covers common side effects, the rare serious ones, and how to report a problem.
Other treatments a provider may consider
- Weekly subcutaneous injection
Compounded Semaglutide
A weekly GLP-1 injection that supports appetite regulation, available only when an independent licensed provider determines a prescription is appropriate.
- Sublingual troche
Semaglutide Troche
A needle-free form of semaglutide that dissolves under the tongue, with lower systemic exposure than the weekly injection — an option a provider may consider where it fits.
- Weekly injection
MIC+B12 Injections
A supportive blend of methionine, inositol, choline, and vitamin B12 that a provider may add alongside a broader weight-loss plan — not a weight-loss medication on its own.
Prescription required. Compounded medications are not approved or evaluated by the FDA for safety, effectiveness, or quality. A licensed provider will determine whether treatment is appropriate for you.
The right treatment is a decision.
Whether tirzepatide, semaglutide, or no medication at all is appropriate for you is a clinical judgment. A two-minute assessment starts the conversation with an independent licensed provider.
Get StartedNo commitment required to complete the assessment.